|Mr. Alfred F. Altomari||Chairman & CEO||733.14k||N/A||1959|
|Mr. Scott M. Coiante||CFO & Sr. VP||434.52k||N/A||1967|
|Dr. Elizabeth Ijeoma Onyemelukwe Garner||Sr. VP & Chief Medical Officer||532.43k||N/A||1968|
|Ms. Mary Coleman||Head of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Geoffrey P. Gilmore||Gen. Counsel||N/A||N/A||1966|
Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Agile Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.